drugset
drugset / Trial / NCT06072040

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia

NCT06072040 ↗

Phase 1/2 Terminated 3 enrolled Auregen Biotherapeutics, SA
NaSingle-groupOpen-labelTreatment

Summary

AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.

Timeline

Start
2024-01-26
Primary completion
2025-11-14
Completion
2025-11-14

Outcome

Outcome not reported

Stopped (Business): “Business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject AUR-201 Cell therapy — Subcutaneous

Indications

microtia